Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

https://doi.org/10.1016/j.bmcl.2003.12.007Get rights and content

Abstract

3,7-Diarylsubstituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility.

Section snippets

Acknowledgments

We thank Kenneth D. Anderson for solubility determination. We also thank Dr. Art Coddington, Dr. Chuck Ross and Dr. Harri Ramjit for mass spectral analyses.

References (17)

  • A.P Adamis et al.

    Biochem. Biophys. Res. Commun.

    (1993)
  • M Detmar

    Dermatol. Sci.

    (2000)
  • D Lu et al.

    Int. J. Cancer

    (2002)
  • R.L Kendall et al.

    J. Biol. Chem.

    (1999)
  • A Giatromanolaki et al.

    J. Path.

    (2001)
  • P Carmeliet et al.

    Nature

    (2000)
    J Folkman

    Nature Med.

    (1995)
There are more references available in the full text version of this article.

Cited by (48)

  • New fluorescent heterocyclic systems from imidazo[1,2-a]pyridine: Design, synthesis, spectral studies and quantum-chemical investigations

    2017, Journal of Molecular Structure
    Citation Excerpt :

    Among various heterocycles, imidazo[1,2-a]pyridines are an important class of heterocyclic compounds. They are found in many biologically active compounds such as antiviral [1], anticancer [2], anxiolytic [3], antimalarial [4], hypnotic [5], antiprotozoal [6] and anti-inflammatory [7] agents, which has rendered this ring system quite an attractive target. This heterocycle continues to be a very popular scaffold for the development of new bioactive molecules, which is maybe due to its simple preparation together with the success of some drugs possessing this skeleton.

  • Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities

    2017, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Therefore, because of a lack of selectivity, potency, and/or pharmacokinetic properties current Nek2 inhibitors are not optimized to further elucidate Nek2 cancer biology and Nek2 as a therapeutic target. A significant bioisostere of benzimidazole is imidazo[1,2-a]pyridine, which has been identified as a kinase-targeting scaffold that reversibly engages the ATP binding domain (hinge) of a protein kinase through hydrogen-bonding [24–30]. In order to identify highly potent and selective Nek2 inhibitors with adequate in vitro and in vivo antitumor activity, we further investigated the replacement of a benzimidazole-core with an imidazo[1,2-a]pyridine-core (MBM-1).

  • Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation

    2014, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Based on the structure of compound 1, the warhead region (imidazopyridine) is predicted to bind to the RET hinge, while the phenyl ring system is predicted to engage a lipophilic pocket adjacent to the RET allosteric pocket. This is an atypical binding modality [32], permitting the fragment to bind the kinase ‘backward’ in comparison to the typical binding of ATP to the active site. Computational modeling showed the phenyl ring system was in close proximity to the allosteric pocket on RET and therefore adding allosteric functionality to compound 1 was hypothesized to increase potency (Fig. 1, B).

View all citing articles on Scopus
View full text